Published in final edited form as:

Tetrahedron. 2011 December 30; 67(52): 10208–10211. doi:10.1016/j.tet.2011.09.147.

Studies on the synthesis of amidoximes from nitroalkanes

Gabriella Sanguineti, Hoang V. Le, and Bruce Ganem*

Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301

Abstract

The reaction of primary nitroalkanes with magnesium or lithium amides provides a convenient, one-step synthesis of substituted amidoximes.

Introduction

As part of our ongoing effort to expand the repertoire of synthetically useful multicomponent reactions (MCRs), we recently disclosed a new synthesis of substituted indoles from nitroalkanes and arylhydrazines in the presence of base.¹ The success of the method relied on transforming the derived nitronate anion **2** (Scheme 1) either to the monoprotonated *aci*-nitro species **3** or to the di-protonated iminium species **4**, with subsequent hydrazine addition and N/N interchange to produce arylhydrazone **5**.

This indole synthesis was inspired by two early patents reporting successful nucleophilic additions of thiols to nitronates leading to thiohydroximate esters **9** (Scheme 2).² Although no mechanism was proposed in the patents, one likely sequence of transformations is depicted in Scheme 2.³ We wondered whether the analogous reaction of nitronates with primary or secondary amines, either alone or in the presence of a thiol or some other catalyst, would afford the corresponding amidoximes **10**. Such amidoximes are of considerable medicinal interest. Besides being involved in the biosynthesis of NO, they display potent pharmacological activity as anticoagulants, platelet inhibitors, antimicrobial agents and matrix metalloprotease inhibitors.⁴ We now report our systematic study of this transformation, as well as the scope and generality of organolithium and magnesium-mediated conversion of nitroalkanes into amidoximes **10**.

Results and Discussion

Using 1-nitropropane as a model nitroalkane, we successfully prepared the corresponding thiohydroximate ester **9** ($R^1 = \text{CH}_3$, $R = \text{Ph}$) using thiophenol according to published conditions ($\text{NaOCH}_3\text{--CH}_3\text{OH}$, reflux).² Given Pergamon that **9** is an oximino analog of a thioester, we expected it to react smoothly with an amine nucleophile to furnish the corresponding amidoxime **10**. However, the reaction of **9** with aniline (CH_3OH , reflux) was extremely sluggish, and afforded a complex mixture of products. Besides obtaining the hoped-for propionamidoxime **10** ($R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Ph}$), we also identified the

© 2011 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1 607 255 7360; bg18@cornell.edu.

This paper is dedicated to Gilbert Stork, an inspiring teacher and research mentor, on the occasion of his ninetieth birthday

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

corresponding N,N'-diphenylpropionamidine. Both products were formed in low yield. Control experiments established that the amidine was derived from **10**.^{5,6}

Taken together, the surprisingly low reactivity of thiohydroximates and the unexpected susceptibility of amidoximes to further nucleophilic addition by amines indicated that the thiohydroximate pathway from nitroalkanes would not likely afford a viable route to amidoximes. We decided to explore instead the direct reaction of 1-nitropropane with nucleophilic amines. After numerous attempts, however, we were unable to identify conditions under which a primary or secondary amine (*n*-butylamine, aniline, pyrrolidine) would react with 1-nitropropane either neat or in a protic (methanol) or aprotic (DMSO) solvent, even at elevated temperatures, to form detectable quantities of the corresponding amidoxime.

We next considered the possibility of boosting the nucleophilicity of the amine component by metallation. A little-cited 1988 Russian report describes the reaction of nitromethane and nitroethane with magnesium *t*-butylamide (2.5 equiv, prepared using EtMgBr and *t*-butylamine at rt in THF) to afford the corresponding N-*t*-butylformamidoxime and N-*t*-butylacetamidoxime in 40 and 45% yields, respectively.⁷

In applying the published procedure to various combinations of nitroalkanes and amines we observed that EtMgCl metallated the amine component only sluggishly at rt. Therefore, to ensure complete consumption of the Grignard reagent, the amine was added to EtMgCl in THF at reflux with continued heating until gas evolution ceased prior to adding the nitroalkane.

To ascertain whether the yield of amidoxime could be improved using different metallated amines, we studied the reaction of 1-nitropropane and *n*-butylamine using various metallating agents. The results are shown in Table 1.

As indicated in Table 1, promising results were obtained in this pilot study using lithium amides. We therefore undertook a side-by-side comparison of magnesiated (Method A) versus lithiated (Method B) amides in the synthesis of amidoximes derived from various primary and secondary amines. Those data are summarized in Table 2.

Data in Table 2 indicate that, perhaps not surprisingly, the yield of amidoxime was affected by steric factors in the primary amines. More interestingly, however, the data suggest that *n*-butyllithium was the preferred reagent for preparing N-(primary alkyl) or N-(secondary alkyl) amidoximes. Metalation using Grignard reagents was preferred in making amidoximes from *t*-butylamine or pyrrolidine.

Having tested the effects of various metallating agents and of amine structure, the amidoxime synthesis was further applied to several different nitroalkanes in order to expand its scope and generality. In so doing, the use of additional amine components, including unsaturated amines and anilines, was also explored. Figure 1 below depicts the structures of the various new amidoximes that were synthesized from nitromethane, nitroethane and 1-nitropropane. Each structure in the figure also indicates the optimal method of preparation, and the yield obtained.

Despite the strongly basic conditions involved, the method generally affords amidoximes, although in moderate yields. Attempts to prepare amidoxime **10i** from allylamine were unsuccessful using Method B, probably because of polyolithiation, which has been reported to be THF-catalyzed.⁸ However, by switching to Method A, **10i** could be synthesized in low yield.

The amidoxime synthesis seemed to work best using anilines, as indicated by the formation of amidoximes **10f** and **10j**. Besides being notable for its yield (68%), the successful preparation of **10j** establishes that the method tolerates the presence of some reactive (trifluoromethyl, nitrile) functionality in the amine component.

In summary, we have investigated the effect of metallating agent and amine substitution pattern in the condensation of nitronate anions with amide anions to produce amidoximes, an important family of medicinally active compounds. Two generally useful sets of conditions were developed and applied to the preparation of a representative family of amidoximes. The results we report establish a useful new dimension to the chemistry of primary nitroalkanes, which are already important building blocks in organic synthesis.

Experimental Section

^1H NMR and ^{13}C NMR spectra were taken on a Varian Mercury-300 or a Varian Inova-400 spectrometer using CDCl_3 with 0.05% v/v TMS or $\text{DMSO}-d_6$ as solvents, recorded in δ (ppm), and referenced to TMS (0.00 ppm for ^1H NMR and 77.16 ppm for ^{13}C NMR) or $\text{DMSO}-d_6$ (2.50 ppm for ^1H NMR and 39.52 ppm for ^{13}C NMR). IR spectra were obtained using a Thermo Nicolet Avatar 370DTGS FT-IR spectrometer and recorded in wavenumbers (cm^{-1}). Melting points were measured using a Thomas Hoover Uni-melt Capillary Melting Point Apparatus or a Mel-Temp Apparatus. Mass spectra were measured at the Life Sciences Core Laboratories Center using ABI/MDS Sciex 4000 Q Trap. Chemicals were obtained from Aldrich, Acros, Aensar, Fisher, or Matrix Scientific, and used as received unless otherwise specified.

General Procedure for the Synthesis of Amidoximes Using Ethylmagnesium Chloride (Method A)

A solution of ethylmagnesium chloride (2 mL of 2 M solution in THF, 4 mmol) in dry THF (2 mL) in a nitrogen-flushed 2-neck 50 mL RBF fitted with a condenser and septum was brought to reflux, and the amine (4 mmol, freshly distilled over sodium hydride) was added neat dropwise. The resulting solution was stirred at reflux until the evolution of ethane gas was complete. The oil bath was lowered, and nitroalkane (1 mmol, freshly distilled over sodium hydride) was added dropwise. The septum was replaced with a glass stopper, and the resulting solution was brought to reflux for 3h. The reaction solution was cooled to 0 °C and acidified to pH 2 with 3 M aqueous HCl. The bulk of THF was removed in vacuo and the residual aqueous phase was washed with ethyl ether (4 × 5 mL), cooled to 0 °C and then basified to pH 10 using 3 M NaOH. The resulting viscous suspension was saturated with sodium chloride and extracted with ethyl ether (4 × 10 mL; caution: emulsions may form). The combined ether layers were washed with brine, dried (MgSO_4), filtered, and concentrated in vacuo to afford the desired amidoxime.

General Procedure for the Synthesis of Amidoximes Using *n*-Butyllithium (Method B)

A solution of amine (4 mmol, freshly distilled over sodium hydride) in dry THF (1.5 mL) in a nitrogen-flushed 2-neck 50 mL RBF fitted with a condenser and septum was cooled to -78 °C, then *n*-butyllithium (2.5 mL of 1.6 M solution in hexanes, 4 mmol) was added. After warming the reaction mixture to rt and then back to 0 °C, nitroalkane (1 mmol, freshly distilled over sodium hydride) was added dropwise. The septum was replaced with a glass stopper, and the resulting suspension was brought to reflux for 3h, (note: the stir bar was agitated to dislodge any solids sticking to the walls of the flask). The reaction suspension was cooled to 0 °C and acidified to pH 2 with 3 M HCl. The bulk of THF was removed in vacuo and the residual aqueous phase was washed with ethyl ether (4 × 5 mL), cooled to 0 °C and then basified to pH 10 using 3 M NaOH. The resulting mixture was saturated with

sodium chloride and extracted with ethyl ether (4×10 mL). The combined ether layers were washed with brine, dried (MgSO_4), filtered, and concentrated in vacuo to afford the desired amidoxime.

Amidoxime 10a—The product was obtained as an orange oil (86 mg, 59%), and ^1H NMR and IR matched literature values:⁹ ^1H NMR (400 MHz, CDCl_3) δ 8.52 (br, 1 H), 5.14 (br s, 1 H), 3.10 (m, 2 H), 2.23 (q, $J=7.5$ Hz, 2 H), 1.49 (m, 2 H), 1.36 (m, 2 H), 1.14 (t, $J=7.5$ Hz, 3 H), 0.93 (t, $J=7.5$ Hz, 3 H). ^{13}C NMR (400 MHz, CDCl_3) δ 156.3, 41.8, 33.1, 22.2, 19.9, 13.8, 10.9. IR (neat) 3233 (br), 2959 (s), 2933 (s), 2873 (s), 1645 (s).

Amidoxime 10b—The product was obtained as a yellow solid (46 mg, 32%): ^1H NMR (400 MHz, CDCl_3) δ 8.24 (br, 1 H), 5.30 (br s, 1 H), 2.40 (q, $J=7.5$ Hz, 2 H), 1.33 (s, 9H), 1.16 (t, $J=7.5$ Hz, 3H). ^{13}C NMR (400 MHz, CDCl_3) δ 156.2, 50.6, 31.5, 23.7, 11.0. IR (CH_2Cl_2) 3241 (br), 2974(s), 2939 (m), 2877 (m), 1633 (s). ESI-MS (CH_3OH) 144.9 (M+H), 167.2 (M+Na), 183.2 (M+K).

Amidoxime 10c—The product was obtained as an orange solid (80.7 mg, 47%): ^1H NMR (400 MHz, CDCl_3) δ 8.39 (br, 1 H), 5.13 (br d, $J=9.7$ Hz, 1 H), 3.13 (m, 1 H), 2.24 (q, $J=7.5$ Hz, 2 H), 1.88 (m, 2 H), 1.75 (m, 2 H), 1.60 (m, 2 H), 1.37-1.15 (m, 2 H), 1.14 (t, $J=7.5$ Hz, 3 H). ^{13}C NMR (400 MHz, CDCl_3) δ 155.5, 50.6, 35.3, 25.4, 25.2, 22.2, 11.3. IR (CH_2Cl_2) 3207 (br), 2932(s), 2853 (s), 1641 (s). ESI-MS (CH_3OH) 171.2 (M+H), 193.2 (M+Na), 209.2 (M+K).

Amidoxime 10d—The product was obtained as an orange solid (65 mg, 46%): ^1H NMR (400 MHz, CDCl_3) δ 8.89 (br, 1 H), 3.26 (m, 4H), 2.53 (q, $J=7.6$ Hz, 2 H), 1.86 (m, 4H), 1.17 (t, $J=7.6$ Hz, 3 H). ^{13}C NMR (400 MHz, CDCl_3) δ 160.8, 46.4, 25.0, 19.6, 10.7. IR (CH_2Cl_2) 3207 (br), 2967(s), 2874 (s), 1628 (s). ESI-MS (CH_3OH) 143.04 (M+H), 165.1 (M+Na), 181.2 (M+K).

Amidoxime 10e—The crude product was obtained as a yellow oil, of which a portion was purified by silica gel flash column chromatography (ethyl acetate, $R_f = 0.30$) to afford a yellow oil (69 mg, calculated total yield 44%): ^1H NMR (400 MHz, CDCl_3) δ 9.47 (br, 1 H), 7.43-7.04 (m, 5 H), 5.62 (br s, 1 H), 4.31 (d, $J=5.1$ Hz, 2 H), 2.21 (q, $J=7.5$ Hz, 2 H), 1.11 (t, $J=7.5$ Hz, 3 H). ^{13}C NMR (400 MHz, CDCl_3) δ 156.1, 139.4, 128.7, 127.3, 126.8, 45.9, 22.1, 10.9. IR (neat) 3206 (br), 3085 (s), 3061 (s), 3028 (s), 2974 (s), 2935 (s), 2874 (s), 1646 (s). ESI-MS (CH_3OH) 179.1 (M+H).

Amidoxime 10f—The product was purified by silica gel flash column chromatography (1:1 ethyl acetate:hexanes, $R_f = 0.30$) to afford a yellow solid (92 mg, 56%): ^1H NMR (400 MHz, CDCl_3) δ 9.79 (br, 1 H), 7.30 (m, 2 H), 7.18-6.99 (m, 3 H), 2.39 (q, $J=7.5$ Hz, 2 H), 1.02 (t, $J=7.5$ Hz, 3 H). ^{13}C NMR (400 MHz, CDCl_3) δ 154.2, 139.0, 129.2, 124.6, 124.2, 22.6, 10.8. IR (CH_2Cl_2) 3187 (br), 2978 (m), 2939 (m), 2877 (m), 1641 (s), 1598 (s). ESI-MS (CH_3OH) 165.0 (M+H).

Amidoxime 10g—The product was obtained as a light yellow solid (47 mg, 41%, mp 73–75 °C): ^1H NMR and ^{13}C NMR matched with literature⁷ values: ^1H NMR (400 MHz, CDCl_3) δ 9.29 (br, 1 H), 6.85 (d, $J=11.1$ Hz, 1 H), 5.17 (br d, $J=11.1$ Hz, 1 H), 1.25 (s, 9 H). ^{13}C NMR (400 MHz, CDCl_3) δ 142.6, 50.0, 30.6.

Amidoxime 10h—The product was obtained as an orange solid (50.7 mg, 40%): ^1H NMR matched with literature¹⁰ values: ^1H NMR (400 MHz, CDCl_3) δ 8.88 (br, 1 H), 3.25 (m, 5 H), 2.06 (s, 3 H), 1.86 (m, 5 H). ^{13}C NMR (400 MHz, CDCl_3) δ 156.6, 46.7, 25.0, 11.9.

Amidoxime 10i—The product was obtained as a yellow solid (29.4 mg, 26%): ^1H NMR (300 MHz, CDCl_3) δ 9.59 (br, 1 H), 5.86 (m, 1 H), 5.42 (br s, 1 H), 5.17 (m, 2 H), 3.75 (s, 2 H), 1.85 (s, 3 H). ^{13}C NMR (300 MHz, CDCl_3) δ 152.9, 135.8, 115.6, 44.8, 14.7. IR (CH_2Cl_2) 3241 (br), 3081(m), 2928 (m), 2859 (m), 1651 (s). ESI-MS (CH_3OH) 115.12 (M+H).

Amidoxime 10j—The crude product was obtained as a yellow solid, of which a portion was purified by trituration with CH_2Cl_2 (2×2 mL) to afford a yellow solid (143 mg, calculated total yield 68%, mp. 160.5–162 °C). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.85 (s, 1 H), 9.12 (s, 1 H), 8.16 (d, $J=2.0$ Hz, 1 H), 7.91 (d, $J=8.6$ Hz, 1 H), 7.78 (dd, $J_1=8.6$ Hz, $J_2=2.0$ Hz, 1 H), 2.02 (s, 3 H). ^{13}C NMR (300 MHz, $\text{DMSO}-d_6$) δ 151.3, 145.9, 136.0, 131.6 (q, $J=31.8$ Hz), 124.6, 120.9, 119.8, 116.5, 114.5 (q, $J=5.3$ Hz), 13.9. IR (CHCl_3) 3356 (s), 3320 (m), 3249 (m), 3105 (m), 2228 (s), 1612 (s), 1544 (s). ESI-MS (CH_3OH) 244.08 (M+H).

Acknowledgments

Funding was provided by the NIH (GM 008500 Training Grant Support for HVL). Support of the Cornell NMR Facility has been provided by NSF (CHE 7904825; PGM 8018643) and NIH (RR02002).

References

1. Simoneau CA, Strohl AM, Ganem B. *Tetrahedron Lett.* 2007; 48:1809. [PubMed: 18320007]
2. (a) Copenhaver, JW. U.S. Patent 2,786,865, 1957. *Chem Abs* 1957. p. 77105(b) Buchanan, JB. U.S. Patent 3,787,470, 1974. *Chem Abs* 1974. p. 82059
3. Keller TH, Yelland LJ, Benn MH. *Can. J. Chem.* 1984; 62:437.
4. Reviews: (a) Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Varella EA, Nicolaides DN. *Curr. Pharm. Design.* 2008; 14:1001. (b) Nicolaides DN, Varella EA. Patai S. *The Chemistry of Acid Derivatives.* 1992; Vol 2 Suppl. B John Wiley & Sons:875.
5. While amidines have been prepared by reductive deoxygenation of amidoximes,⁶ to our knowledge the transformation of **10** into N,N'-diphenylpropionamidine appears to be the first example of an amidoxime-to-amidine transformation by nucleophilic addition and elimination of NH_2OH .
6. Mull RP, Mizzoni RH, Dapero MR, Egbert ME. *J. Med. Chem.* 1962; 5:651.(b) Nadrah K, Dolenc MS. *Synlett.* 2007:1257.
7. Apasov ET, Kalinin AV, Strelenko YA, Tartakovskii VA. *Izv. Akad. Nauk. SSSR.* 1988:2873.
8. (a) Katritzky AR, Piffi M, Lang H, Anders E. *Chem Rev.* 1999; 99:665. [PubMed: 11749429] (b) Jacobson MA, Keresztes I, Williard PG. *J. Am. Chem. Soc.* 2005; 127:4965. [PubMed: 15796563]
9. Un R, Sumengen D. *Chim. Acta Turc.* 1976; 4:131.
10. Bushey DF, Hoover FC. *J. Org. Chem.* 1980; 45:4198.

Figure 1.

Scheme 1.
Nitro to indole conversion

Scheme 2.

Proposed mechanism of nitroalkane to thiohydroxamate conversion

Table 1Yields of N-(*n*-butyl)propionamidoxime from 1-nitropropane using various metallating agents

Base	% Yield
EtMgCl	28
EtMgCl/cat CuCl	27
<i>n</i> -BuLi	58
NaH	27

Table 2

Effect of metallating agent on the synthesis of N-alkylpropionamidoximes

Amine	Yield w/ EtMgCl Method A	Yield w/ <i>n</i> -BuLi Method B
<i>n</i> -butylamine	28%	59%
cyclohexylamine	32%	47%
<i>t</i> -butylamine	32%	19%
pyrrolidine	46%	26%